title: Adalimumab for sight-threatening uveitis in Behçet's disease.
abstract: OBJECTIVE
  To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy.
  
  
  METHODS
  Case note review. Main outcome measure was recurrence of uveitis.
  
  
  RESULTS
  All patients remained free of recurrence with stable visual acuities.
  
  
  CONCLUSIONS
  Adalimumab appears to maintain disease remission in Behçet's disease.
authors.affiliation: Birmingham and Midland Eye Centre, Birmingham, UK.
authors.forename: B
authors.initials: B
authors.lastname: Mushtaq
authors.forename: T
authors.initials: T
authors.lastname: Saeed
authors.forename: R D
authors.initials: RD
authors.lastname: Situnayake
authors.forename: P I
authors.initials: PI
authors.lastname: Murray
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001528:Behcet Syndrome / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D012008:Recurrence; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014605:Uveitis / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab